贝纳利祖马布用于过敏性喘:一个随机,双盲,安慰剂对照的试验
Gail M Gauvreau1, Roma Sehmi2, J Mark FitzGerald3,4
1Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada gauvreau@mcmaster.ca.
The European respiratory journal
|July 26, 2024
概括
贝纳利祖马布在过敏性喘患者中有效降低了乙氨基酸,但没有显著改变晚期喘反应,这表明乙氨基酸不是支气管收缩的唯一驱动因素.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 众所周知,本拉利祖马布可以快速耗尽血液和肺组织中的乙氨基细胞.
- 这项研究旨在确定本拉利祖马布是否可以降低过敏性喘患者的过敏原诱导晚期喘反应 (LAR).
研究的目的:
- 为了评估本拉利祖马布在减轻过敏原诱导的晚期喘反应 (LAR) 的疗效,在过敏性喘患者.
- 为了评估本拉利祖马布在过敏原挑战后对血液,唾液,骨髓和支气管组织中氨基基基水平的影响.
主要方法:
- 一项随机对照试验,涉及过敏性喘和唾液中异氨基和LAR升高的参与者.
- 参与者接受了本拉利祖马布或安慰剂8周,在第9周和第12周接受过敏原挑战,以评估乙素细胞数量和LAR.
主要成果:
- 与安慰剂相比,本拉利祖马布显著降低了血液,唾液和骨髓中的乙氨基基细胞.
- 虽然在本拉利祖马布组中,唾液异敏症在过敏后的挑战中减弱,但晚期喘反应 (LAR) 没有显著差异.
- 与安慰剂组 (60.9%) 相比,本拉利祖马布组 (30.4%) 的不良事件发生频率较低.
结论:
- 在轻度过敏性喘患者中,八周的本拉利祖马布治疗显著减少了血液,骨髓和唾液中的埃索诺菲利亚.
- 晚期喘反应 (LAR) 缺乏变化表明,乙素可能不是过敏原引起的支气管收缩的主要因素.
更多相关视频
09:58A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
22.4K
06:34A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
Published on: June 4, 2017
10.0K
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
264
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
264
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
244
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
244
01:19Antiasthma Drugs: Leukotriene Modifiers
268
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
268
01:20Asthma: Pathogenesis and Management
379
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
379
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K